STAHL'S | CHAPTER 7 | ANTIDEPRESSANTS | COMPLETE | #psychiatry#psychopharmacology

Easy to understand notes of Stahl's Essential Psychopharmacology, Chapter 7-ANTIDEPRESSANTS. THIS VIDEO WILL DISCUSS: GENERAL PRINCIPLES RESPONSE REMISSION RECOVERY RELAPSE RECURRENCE HOW WELL DO ANTIDEPRESSANTS WORK IN THE REAL WORLD? REMISSION RATES IN MDD COMMON RESIDUAL SYMPTOMS ANTIDEPRESSANT CLASSES SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) FLUOXETINE SERTRALINE PAROXETINE FLUVOXAMINE CITALOPRAM ESCITALOPRAM SEROTONIN PARTIAL AGONIST/REUPTAKE INHIBITORS (SPARIS) BUSPIRONE VILAZODONE SEROTONIN–NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) VENLAFAXINE DESVENLAFAXINE DULOXETINE MILNACIPRAN NOREPINEPHRINE–DOPAMINE REUPTAKE INHIBITORS (NDRIS) BUPROPION SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITORS (NRIS) AGOMELATINE ALPHA-2 ANTAGONIST ACTIONS AND MIRTAZAPINE MIANSERIN SETIPTILINE SEROTONIN ANTAGONIST/REUPTAKE INHIBITORS (SARIS) TRAZODONE NEFAZODONE CLASSIC ANTIDEPRESSANTS: MAO INHIBITORS THE DIETARY TYRAMINE INTERACTION MOCLOBEMIDE DRUG–DRUG INTERACTIONS FOR MAOIS MAOIS AND SYMPATHOMIMETICS: TO AVOID OR ADMINISTER WITH CAUTION MAOI INTERACTIONS WITH ANESTHETICS MAOI INTERACTIONS WITH TCAS MAOI INTERACTIONS WITH OPIOIDS SWITCHING TO AND FROM MAOIS, AND BRIDGING MEDICATIONS TO USE DURING THE SWITCHES CLASSIC ANTIDEPRESSANTS: TRICYCLIC ANTIDEPRESSANTS AUGMENTING ANTIDEPRESSANTS L-5-METHYLTETRAHYDROFOLATE (L-METHYLFOLATE): MONOAMINE MODULATOR S-adenosyl-methionine (SAMe) THYROID BRAIN STIMULATION: CREATING A PERFECT STORM IN BRAIN CIRCUITS OF DEPRESSED PATIENTS ELECTROCONVULSIVE THERAPY TRANSCRANIAL MAGNETIC STIMULATION DEEP BRAIN STIMULATION PSYCHOTHERAPY AS AN EPIGENETIC “DRUG” HOW TO CHOOSE AN ANTIDEPRESSANT SYMPTOM-BASED ANTIDEPRESSANT SELECTIONS CHOOSING AN ANTIDEPRESSANT FOR WOMEN BASED ON THEIR LIFE CYCLE DEPRESSION AND ITS TREATMENT DURING CHILDBEARING YEARS AND PREGNANCY CHOOSING AN ANTIDEPRESSANT ON THE BASIS OF GENETIC TESTING SHOULD ANTIDEPRESSANT COMBINATIONS BE THE STANDARD FOR TREATING UNIPOLAR MAJOR DEPRESSIVE DISORDER? TRIPLE-ACTION COMBO: SSRI/SNRI ± NDRI FUTURE TREATMENTS FOR MOOD DISORDERS NMDA BLOCKADE MULTIMODAL AGENTS